QurAlis

QurAlis

We now have an unprecedented deep understanding of the disease and the disease mechanisms which creates an opportunity to realize real treatment breakthroughs.
More Details

About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.

Recent Milestones (last six months)
European HQ opening
UK Clinical Trial Authorisation (CTA) for QRL-201
Unlearn collaboration
EU CTA for QRL-201

Products
QRL-101 - Kv7 (small molecule)
QRL-201 - STATHMIN-2 (ASO)
QRL-204 - UNC13A (ASO)

Investors
EQT Life Sciences
Sanofi Ventures
Droia Ventures
LS Polaris Innovation Fund
Lilly
Amgen
Mission Biocapital
Dementia Discovery Fund
Inkef Capital
ALS Investment Fund
Dolby Family Ventures
MP Healthcare Venture Management Inc.
Mitsui Global Investment
Mass General Brigham

Full Company Address and Contact Details
QurAlis Corporation
100 Cambridgepark Drive
Cambridge, MA 02140
CONTACT: Kasper Roet, PhD, CEO and founder